Intercil (glaucoma implant)

History

2025: Product Announcement

At the end of August 2025, Ciliatech, based in Chavano (France), introduced the Intercil eye implant, developed to treat glaucoma. The device can be used in the treatment of adult patients aged 18 years and older.

According to the World Health Organization (WHO), glaucoma is one of the leading causes of visual impairment and blindness on a global scale. This ailment is accompanied by a constant or periodic increase in intraocular pressure above the level acceptable to humans. Increased pressure negatively affects the optic nerve, leading to a deterioration in its blood supply: as a result, after some time, the nerve dies off. The disease is characterized by rapid progression and can lead to irreversible blindness.

𝓲

Фото: Ciliatech

The Intercil implant is designed to reduce intraocular pressure by increasing uveoscleral outflow. This pathway suggests that fluid movement occurs through the ciliary muscle into the suprachorioid space, and then into the choroid and suprachorioid slits, further from the eye through the perivascular spaces of emissary scleral channels or directly through permeable bundles of scleral collagen.

A feature of the Intercil product is that it reduces intraocular pressure without penetrating the anterior chamber of the eye. This potentially contributes to minimizing the risk of corneal endothelial cell loss. It is also possible to position 360 degrees around the patient's eye to achieve optimal positioning. The device is suitable for people with narrow-angle glaucoma. It is also effective in the treatment of primary open-angle and primary closed-angle glaucoma.^[1]

Notes